SEC Filings

Filing links are provided when reliable SEC filing data is available.

Recent Filings

Form	Filing Date	Accepted	Document
SC 13G	Aug 19, 2026	Aug 19, 2026	View filing
SC 13G	Aug 13, 2026	Aug 13, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 5, 2026	Aug 5, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
4	Jun 8, 2026	Jun 8, 2026	View filing
3	Jun 8, 2026	Jun 8, 2026	View filing
S-8	Jun 5, 2026	Jun 5, 2026	View filing
8-K	Jun 5, 2026	Jun 5, 2026	View filing
4	May 20, 2026	May 20, 2026	View filing
SC 13G	May 12, 2026	May 12, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 6, 2026	May 6, 2026	View filing
EFFECT	May 5, 2026	May 6, 2026	View filing
SC 13G/A	Apr 29, 2026	Apr 29, 2026	View filing
CORRESP	Apr 24, 2026	Apr 24, 2026	View filing
4	Apr 24, 2026	Apr 24, 2026	View filing
3	Apr 24, 2026	Apr 24, 2026	View filing
ARS	Apr 23, 2026	Apr 23, 2026	View filing
DEFA14A	Apr 23, 2026	Apr 23, 2026	View filing
DEF 14A	Apr 23, 2026	Apr 23, 2026	View filing
8-K	Apr 22, 2026	Apr 22, 2026	View filing
3	Apr 13, 2026	Apr 13, 2026	View filing
3	Apr 13, 2026	Apr 13, 2026	View filing
8-K	Apr 2, 2026	Apr 2, 2026	View filing

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

Washington, DC

533 employees

www.vandapharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mihael H. Polymeropoulos

View full financials